Home  »  Technologies   »  Amryt Pharma plc (AMYT) Has A Bright Growth Prospe...

Amryt Pharma plc (AMYT) Has A Bright Growth Prospects For 2023

Amryt Pharma plc (NASDAQ:AMYT) has seen 1.85 million shares traded in the recent trading session. The company, currently valued at $617.87M, closed the recent trade at $14.56 per share which meant it lost -$0.04 on the day or -0.27% during that session. The AMYT stock price is -1.44% off its 52-week high price of $14.77 and 61.47% above the 52-week low of $5.61. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.36 million shares traded. The 3-month trading volume is 421.43K shares.

The consensus among analysts is that Amryt Pharma plc (AMYT) is a Hold stock at the moment, with a recommendation rating of 2.70. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 6 out of 7 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.05.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Amryt Pharma plc (NASDAQ:AMYT) trade information

Sporting -0.27% in the red today, the stock has traded in the red over the last five days, with the highest price hit on Monday, 01/23/23 when the AMYT stock price touched $14.56 or saw a rise of 1.22%. Year-to-date, Amryt Pharma plc shares have moved 100.00%, while the 5-day performance has seen it change -0.82%. Over the past 30 days, the shares of Amryt Pharma plc (NASDAQ:AMYT) have changed 103.63%. Short interest in the company has seen 86860.0 shares shorted with days to cover at 2.97.

Wall Street analysts have a consensus price target for the stock at $20.54, which means that the shares’ value could jump 29.11% from the levels at last check today. The projected low price target is $14.50 while the price target rests at a high of $38.00. In that case, then, we find that the latest price level in today’s session is -160.99% off the targeted high while a plunge would see the stock lose 0.41% from the levels at last check today.

Amryt Pharma plc (AMYT) estimates and forecasts

Figures show that Amryt Pharma plc shares have underperformed across the wider relevant industry. The company’s shares have gained 92.11% over the past 6 months, with this year growth rate of -400.00%, compared to 4.50% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2023 fiscal year revenue. Growth estimates for the current quarter are 28.60% and -108.80% for the next quarter. Revenue growth from the last financial year stood is estimated to be 21.10%.

6 analysts offering their estimates for the company have set an average revenue estimate of $68.37 million for the current quarter. 6 have an estimated revenue figure of $73.5 million for the next quarter concluding in Dec 2022. Year-ago sales stood $56.52 million and $54.83 million respectively for this quarter and the next, and analysts expect sales will grow by 21.00% for the current quarter and 34.10% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 15.10% over the past 5 years.

AMYT Dividends

Amryt Pharma plc is expected to release its next earnings report between March 02 and March 07 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Amryt Pharma plc (NASDAQ:AMYT)’s Major holders

Insiders own 0.08% of the company shares, while shares held by institutions stand at 74.55% with a share float percentage of 74.61%. Investors are also buoyed by the number of investors in a company, with Amryt Pharma plc having a total of 74 institutions that hold shares in the company. The top two institutional holders are Athyrium Capital Management, LP with over 8.86 million shares worth more than $61.91 million. As of Jun 29, 2022, Athyrium Capital Management, LP held 28.66% of shares outstanding.

The other major institutional holder is Highbridge Capital Management, LLC., with the holding of over 6.33 million shares as of Jun 29, 2022. The firm’s total holdings are worth over $44.27 million and represent 20.50% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Bruce & Co., Inc. and Columbia Fds Ser Tr II-Columbia Flexible Capital Income Fd. As of Jun 29, 2022, the former fund manager holds about 1.02% shares in the company for having 0.32 million shares of worth $2.2 million while later fund manager owns 0.17 million shares of worth $1.25 million as of Aug 30, 2022, which makes it owner of about 0.56% of company’s outstanding stock.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts